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Summary
. The median height z-score for paediatric patients on
dialysis was −2.1 and for those with a functioning
transplant −1.3. Children transplanted before the
age of 12 years improved their height z-score over
the subsequent ﬁve years, whereas those older
than 12 maintained their height z-score, with all
transplanted patients having a similar median
height z-score after ﬁve years of starting renal
replacement therapy (RRT).
. The median weight z-score for children on dialysis
was−1.4 whereas children with a functioning trans-
plant had a near normal weight for age and sex with
a median z-score of −0.3.
. Of those with data, 75% of the prevalent paediatric
RRT population had one or more ‘traditional’ risk
factors for cardiovascular disease, with 1 in 10
having all three risk factors present.
. For the 10 centres reporting quarterly laboratory
data, the average creatinine in transplant patients
was 79 mmol/L; dialysis patients had normal average
anaemia and acidosis markers and evidence of
secondary hyperparathyroidism with an average
PTH of 17.3 pmol/L.
. For transplant patients, 80% achieved the systolic
blood pressure (SBP) standard and 93% achieved
the haemoglobin standard.
. For haemodialysis patients, 57% achieved the SBP
standard, 62% achieved the haemoglobin standard,
82% achieved the calcium standard, 51% achieved
the phosphate standard and 39% achieved the
parathyroid hormone (PTH) standard.
. For peritoneal dialysis patients, 70% achieved the
SBP standard, 77% achieved the haemoglobin
standard, 72% achieved the calcium standard, 54%
achieved the phosphate standard and 33% achieved
the PTH standard.
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Introduction
This Report focuses on the following variables for the
prevalent paediatric dialysis and transplantation cohort
on the 31st December 2014:
1. The completeness of data returns to the UK Renal
Registry (UKRR)
2. Anthropometric characteristics and growth
3. Cardiovascular risk factors (CVRFs)
4. Laboratory and clinical indices including anaemia
control and biochemical ﬁndings
Analyses of prevalent paediatric patients aged ,18
years receiving renal replacement therapy (RRT) for the
year 2014 and for the period 2003 to 2014 inclusive are
reported. A single dataset was collected for each patient
per year during this time period. Where possible, analysis
of incident cohorts has been undertaken with centre
speciﬁc data for each paediatric nephrology centre in
the UK also being provided.
In previous years the analyses have been restricted to
those aged under 16 years, this year those aged 16–18
years are also included.
Methods
Processes for data collection for the paediatric UKRR are
described in chapter 4. The data presented in this Report relate
to the annual census date of 31st December 2014.
Standards and standardisation
Standards are in bold text and are from the ‘Treatment of adults
and children with renal failure’, Renal Association standards third
edition (2002) [1] unless otherwise stated.
Where the value of clinical parameters in childhood varies with
age, sex and size, data are presented as z-scores.
Anthropometry
‘Measures of supine length or standing height and weight
should be monitored at each clinic visit. All measurements
should be plotted on European reference growth charts for
healthy children.’
The reference range for height (Ht), weight (Wt) and body
mass index (BMI) in childhood varies with gender and age.
BMI was calculated using the formula BMI =Wt (kg)/Ht2
(m). Height and weight were adjusted for age. To account for
discrepancies in linear growth secondary to renal disease,
BMI was expressed according to height-age, rather than
chronological age. The International Obesity Taskforce deﬁ-
nition [2]was used to deﬁne overweight and obesity; z-scores
were calculated based on the British 1990 reference data for
height and weight [3].
Blood pressure
‘Blood pressure varies throughout childhood and should be
maintained within two standard deviations of the mean for
normal children of the same height and sex. The systolic
blood pressure during peritoneal dialysis or after haemo-
dialysis should be maintained at <90th centile for age, gender
and height.’
‘In paediatric renal transplant patients, the systolic blood
pressure should be maintained at <90th percentile for age,
gender and height.’
The analyses of systolic blood pressure (SBP) in this Report
present the achievement of SBPs at or below the 90th percen-
tile. Guidance for blood pressure in paediatric renal transplant
patients was based on 2011 British Association for Paediatric
Nephrology recommendations [4].
The reference range for SBP varies with gender, age and
height. The data is therefore presented as z-scores based on
data from the fourth report of the National High Blood
Pressure Education Programme working group in the United
States [5].
Cholesterol
The National Heart Lung and Blood Institute recommends
screening for dyslipidaemias in children with chronic kidney
disease/established renal failure/post renal transplant (deemed
high risk) between the ages of 2 and 17, and deﬁnes high total
cholesterol as55.2 mmol/L [6]. This cut-off has been adopted
for this Report.
Haemoglobin (Hb) and Ferritin
Guidance on the management of anaemia in adults and
children with chronic kidney disease was updated and pub-
lished by the National Institute for Health and Care Excellence
in February 2011 (Clinical Guideline 114) [7].
‘Typically maintain the aspirational Hb range between 100
and 120 g/L for young people and children aged 2 years and
older, and between 95 and 115 g/L for children younger
than 2 years of age, reﬂecting the lower normal range in
that age group.’
Haemoglobin and ferritin were analysed using age related
laboratory reference ranges as in table 10.1.
Calcium, phosphate and parathyroid hormone (PTH)
‘Serum phosphate and calcium should be kept within the
normal range. PTH levels should be maintained within
twice the upper limit of the normal range but, contrary to
adult standards, may be kept within the normal range if
growth is normal.’
Calcium, phosphate and PTH were analysed using age related
laboratory reference ranges as in table 10.1. Individual variable
data analysis has been performed per centre and nationally. It
should be noted that ‘normal’ growth is difﬁcult to determine in
the setting of paediatric RRT.
Bicarbonate
‘Serum bicarbonate concentrations should be between 20
and 26 mmol/L.’
Bicarbonate reference ranges vary by centre, and are reported
as within or outside the reference range as given in table 10.1.
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Cardiovascular risk factors
Last year we presented a new cross-sectional evaluation of the
prevalence of traditional risk factors for cardiovascular disease,
including hypertension, overweight/obesity and hypercholestero-
laemia in children with established renal failure (ERF). In this
initial analysis, we showed the prevalence of one or more
CVRFs in children with ERF in the UK. Evidence for the use of
total cholesterol and the relationship of childhood CVRFs with
adult CVRFs is available from The National Heart Lung and
Blood Institute [6].
Statistical analyses
Annual and quarterly clinical and laboratory data have been
analysed separately, with annual data being used unless stated
otherwise. Data were analysed to calculate summary statistics
(maximum, minimum, mean and median values in addition to
standard deviation and quartile ranges). Where applicable, the
percentage achieving the audit standard was also calculated. If a
patient had missing data, they were excluded from the relevant
analyses.
Longitudinal analyses of attainment of standards were also
performed. These were based on a single data point per ERF
patient per year collected as described previously. Caution should
be exercised in the interpretation of analyses based on data items
from a single annual measurement per patient. This is due to
changing audit standards over time and variable data returns for
previous years. Furthermore, for biochemical variables there are
not only differences between assays used at different centres, but
also differences in the timing of the result between modalities to
take into account. All analyses were performed using SAS 9.3.
Results
Data completeness
Annual data
Tables 10.2 and 10.3 show the completeness of annual
data returns for transplant and dialysis patients for 2014.
Overall, completeness was excellent for key variables
in both groups, with the larger group of transplant
patients having slightly better completeness for height,
BMI, SBP and cholesterol and the smaller group of
dialysis patients having somewhat better completeness
for PTH, calcium and phosphate. Ferritin completeness
is relatively low in transplant patients which may reﬂect
satisfactory graft function and anaemia control, or use
of alternative methods of assessing iron stores. Reporting
of therapy for anaemia remains patchy and only half
the patients have a cholesterol value reported to the
paediatric UKRR.
Quarterly data
Ten centres supplied quarterly 2014 data to the UKRR.
Completeness of this data is shown for transplant
patients in table 10.4 and dialysis patients in table 10.5.
For transplant patients, ferritin and PTH were included
in quarterly returns but not widely used; the overall
quarterly completeness for ferritin in transplant patients
was 40%, and for PTH was 46%.
Growth
Height
Figures 10.1 and 10.2 show that children receiving
RRT were short for their age and sex; those on dialysis
were signiﬁcantly shorter than those with renal trans-
plants. The overall median z-score was −1.3 in the
transplanted group and −2.1 in the dialysis group, p ,
0.0001. When taking into account data completeness,
some centres with apparently less desirable transplant
height z-scores had only 54% completeness. Belfast was
excluded from ﬁgure 10.2 as no height data for dialysis
patients was reported. Figure 10.3 demonstrates that by
Table 10.1. Summary of relevant biochemical clinical audit measures
Age
Parameter ,1 year 1–5 years 6–12 years .12 years
Haemoglobin (g/L), NICE guideline CG 114 Maintain 95–115
if aged ,2 years
Maintain 100–120
if aged .2 years
100–120 100–120
Ferritin (mg/L) 200–500 200–500 200–500 200–500
Corrected calcium (mmol/L) 2.24–2.74 2.19–2.69 2.19–2.69 2.15–2.55
Phosphate (mmol/L) 1.10–1.95 1.05–1.75 1.05–1.75 1.05–1.75
Parathyroid hormone (individual centre) Within twice the normal range
Levels may be maintained within normal range if growing appropriately
Bicarbonate (mmol/L) Reported as either within or outside centre reference range
NICE – National Institute for Health and Care Excellence
Paediatric biochemistry Nephron 2016;132(suppl1):237–252 239
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the time of RRT start, children were already short for
their age and sex with an overall median height z-score
of−1.4 (shown by the dotted line) with younger children
aged 2–8 most affected. Figure 10.4 shows that although
transplanted paediatric patients aged up to 12 years
improved their height z-score in the ﬁrst 5 years of start-
ing RRT, those older than 12 started with a better height
z-score which was maintained. In contrast, all dialysis
patients had a worsening height z-score over time. This
was more pronounced in older children, who were better
grown at RRT start. It should be noted that due to
changes in modality, groups are not strictly sequential
in this analysis, and as most patients received a trans-
plant, there are small numbers of dialysis patients at
Table 10.2. Percentage data completeness for transplant patients ,18 years old old by centre for each variable and total number of
patients per centre in 2014
Transplant
patients IV
Centre N Height Weight BMI SBP Hb Creat Ferr ESA Iron Chol Bicarb PTH Ca Phos
Bham_P 79 91.1 91.1 91.1 91.1 91.1 91.1 41.8 0.0 0.0 0.0 91.1 82.3 91.1 91.1
Blfst_P∗ 24 54.2 87.5 54.2 50.0 100.0 100.0 75.0 91.7 8.3 58.3 100.0 41.7 100.0 100.0
Brstl_P∗ 43 97.7 95.4 93.0 95.4 100.0 100.0 62.8 97.7 2.3 53.5 100.0 72.1 100.0 100.0
Cardf_P 22 95.5 100.0 95.5 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Glasg_P∗ 44 100.0 100.0 100.0 100.0 90.9 100.0 61.4 100.0 100.0 47.7 88.6 86.4 88.6 93.2
L Eve_P∗ 79 98.7 98.7 98.7 98.7 98.7 98.7 98.7 94.9 98.7 93.7 98.7 98.7 98.7 98.7
L GOSH_P∗ 157 94.9 96.2 94.3 94.3 96.8 96.8 96.2 22.9 20.4 33.1 96.8 96.8 96.8 96.8
Leeds_P∗ 69 78.3 95.7 78.3 91.3 95.7 95.7 73.9 98.6 98.6 89.9 95.7 72.5 95.7 92.8
Livpl_P 36 88.9 88.9 88.9 88.9 88.9 86.1 83.3 88.9 86.1 69.4 86.1 2.8 88.9 86.1
Manch_P∗ 52 100.0 100.0 100.0 100.0 100.0 100.0 69.2 100.0 100.0 13.5 100.0 100.0 100.0 100.0
Newc_P∗ 30 100.0 100.0 100.0 100.0 100.0 100.0 86.7 100.0 100.0 70.0 96.7 76.7 96.7 96.7
Nottm_P∗ 68 76.5 77.9 76.5 73.5 92.7 94.1 88.2 0.0 0.0 85.3 92.7 89.7 94.1 94.1
Soton_P 23 87.0 95.7 87.0 95.7 100.0 100.0 95.7 95.7 95.7 56.5 100.0 95.7 95.7 100.0
UK 726 90.8 94.2 90.4 91.7 96.0 96.6 80.0 61.3 52.6 54.0 95.6 83.3 95.7 95.7
BMI – body mass index; SBP – systolic blood pressure; Hb – haemoglobin; Creat – creatinine; Ferr – ferritin; ESA – erythropoietin stimulat-
ing agent; IV – intravenous; Chol – cholesterol; Bicarb – bicarbonate; PTH – parathyroid hormone; Ca – calcium; Phos – phosphate
∗Denotes centre undertaking paediatric kidney transplantation
Table 10.3. Percentage data completeness for dialysis patients ,18 years old old by centre for each variable and total number of
patients per centre in 2014
Dialysis
patients IV
Centre N Height Weight BMI SBP Hb Ferr ESA Iron Chol Bicarb PTH Ca Phos
Bham_P 24 95.8 95.8 95.8 100.0 95.8 95.8 0.0 0.0 0.0 95.8 95.8 95.8 95.8
Blfst_P 6 0.0 50.0 0.0 16.7 100.0 83.3 66.7 16.7 66.7 100.0 100.0 100.0 100.0
Brstl_P 14 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 78.6 100.0 92.9 100.0 100.0
Cardf_P 6 83.3 100.0 83.3 100.0 100.0 100.0 100.0 100.0 66.7 100.0 100.0 100.0 100.0
Glasg_P 12 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 58.3 91.7 100.0 100.0 100.0
L Eve_P 20 90.0 100.0 90.0 100.0 100.0 100.0 90.0 100.0 60.0 100.0 100.0 100.0 100.0
L GOSH_P 28 96.4 100.0 96.4 96.4 100.0 82.1 100.0 100.0 64.3 100.0 100.0 100.0 100.0
Leeds_P 17 76.5 100.0 76.5 88.2 100.0 100.0 100.0 100.0 76.5 100.0 100.0 100.0 100.0
Livpl_P 5 60.0 80.0 60.0 80.0 80.0 80.0 80.0 60.0 60.0 60.0 80.0 80.0 80.0
Manch_P 33 90.9 97.0 90.9 93.9 97.0 97.0 100.0 97.0 15.2 100.0 97.0 100.0 100.0
Newc_P 7 100.0 100.0 100.0 100.0 85.7 85.7 100.0 100.0 57.1 85.7 85.7 85.7 85.7
Nottm_P 17 52.9 58.8 52.9 29.4 100.0 94.1 0.0 0.0 52.9 100.0 94.1 100.0 100.0
Soton_P 2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50.0 100.0 50.0 100.0 100.0
UK 191 85.3 93.2 85.3 88.0 97.9 94.2 75.9 74.4 47.6 97.4 96.3 98.4 98.4
BMI – body mass index; SBP – systolic blood pressure; Hb – haemoglobin; Ferr – ferritin; ESA – erythropoietin stimulating agent; IV –
intravenous; Chol – cholesterol; Bicarb – bicarbonate; PTH – parathyroid hormone; Ca – calcium; Phos – phosphate
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ﬁve years after starting RRT. Data for 16–18 year olds was
omitted owing to small group numbers.
The proportion of patients aged 2–18 years with a height
less than two standard deviations in 2014 was much higher
for those on dialysis (55.9% for haemodialysis (HD) and
43.6% for peritoneal dialysis (PD)) compared to those
with a functioning transplant (26.0%), excluding situations
where growthmight be compromised, for example patients
with syndromes and those born prematurely. For trans-
planted patients, the proportion increased with age, with
Table 10.5. Percentage data completeness for dialysis patients ,18 years old old by centre reporting quarterly laboratory data
Dialysis patients
Centre N Hb Ferritin Calcium Phosphate PTH Bicarbonate
Bham_P 24 100.0 75.8 100.0 100.0 100.0 100.0
Blfst_P 6 95.7 91.3 95.7 95.7 95.7 95.7
Brstl_P 14 92.0 84.0 92.0 92.0 92.0 92.0
Cardf_P 6 72.7 72.7 72.7 72.7 63.6 72.7
Glasg_P 12 84.3 78.4 84.3 84.3 80.4 91.7
L Eve_P 20 98.7 94.7 98.7 98.7 96.1 98.7
L GOSH_P 28 99.1 40.5 99.1 99.1 98.3 99.1
Leeds_P 17 100.0 92.4 100.0 100.0 89.4 100.0
Newc_P 7 93.8 93.8 87.5 93.8 87.5 93.8
Nottm_P 17 92.9 92.9 94.3 94.3 92.9 94.3
Overall 151 92.9 81.7 92.4 93.1 89.6 93.8
Hb – haemoglobin; PTH – parathyroid hormone
Table 10.4. Percentage data completeness for transplant patients ,18 years old old by centre reporting quarterly laboratory data
Transplant patients
Centre N Creatinine Hb Calcium Phosphate Bicarbonate
Bham_P 79 85.7 100.0 85.7 85.7 85.7
Blfst_P 24 100.0 95.7 100.0 100.0 100.0
Brstl_P 43 95.2 92.0 92.7 92.1 89.7
Cardf_P 22 74.1 72.7 74.1 74.1 74.1
Glasg_P 44 71.5 84.3 71.5 71.5 88.6
L Eve_P 79 98.0 98.7 98.0 98.0 98.0
L GOSH_P 157 98.0 99.1 97.8 97.4 97.3
Leeds_P 69 90.7 100.0 90.3 88.3 89.1
Newc_P 30 85.1 93.8 85.1 85.1 71.1
Nottm_P 68 87.9 92.9 87.9 87.9 87.4
Overall 615 88.6 92.9 88.3 88.0 88.1
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Fig. 10.1. Median height z-scores for
transplant patients ,18 years old in 2014,
centre speciﬁc and national averages
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20.5% of those aged 5–,12 having a height z-score less
than two standard deviations, 26.3% of those aged 12–
,16 and 32.2% of those aged 16–,18. No comments
can be made at centre level or for dialysis patients due to
small patient numbers. Figure 10.5 shows large variation
in the use of growth hormone in those with a height less
than two standard deviations. The proportion of patients
with a height less than two standard deviations whose
growth hormone status was not known is high (ranging
from approximately 10% in 2010 to 50% in 2011), and
this limits meaningful interpretation. Average use of
growth hormone for patients aged under 18 with a height
less than two standard deviations since 2003 is 26.1% for
dialysis patients and 10.2% for transplant patients.
Weight
Figures 10.6 and 10.7 show that paediatric patients
receiving dialysis were signiﬁcantly more underweight
Centre
H
ei
gh
t z
-s
co
re
–6.0
–5.0
–4.0
–3.0
–2.0
–1.0
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Li
vp
l_
P
L 
G
O
SH
_P
Le
ed
s_
P
G
la
sg
_P
Bh
am
_P
L 
Ev
e_
P
N
ot
tm
_P
Ca
rd
f_
P
N
ew
c_
P
Br
st
l_
P
M
an
ch
_P
So
to
n_
P
U
K
N = 163
 Upper quartile
 Median
 Lower quartile
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for age and sex than those with renal transplants. The
overall median z-score was −0.3 in the transplanted
group and −1.4 in the dialysis group, p , 0.0001. Centre
level comparison for dialysis patients in particular should
be avoided due to low numbers per centre.
When taking height into account and examining BMI
rather than weight alone, ﬁgures 10.8 and 10.9 show that
BMI z-scores are mostly within the upper half of the nor-
mal range for transplant patients, and spread throughout
the normal range in dialysis patients. The majority of
paediatric RRT patients have a BMI within the normal
range, as shown in ﬁgure 10.10.
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Fig. 10.6. Median weight z-scores for
transplant patients ,18 years old in 2014,
centre speciﬁc and national averages
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Cardiovascular risk factor evaluation
Obesity
Figures 10.8 and 10.9 show that children with renal
transplants had a signiﬁcantly higher body mass index
for age and sex than those receiving dialysis. The overall
median z-score was 1.0 in the transplanted group and 0.1
in the dialysis group, p, 0.0001.
Figure 10.10 demonstrates higher proportions of over-
weight and obese children in those with renal transplants
(43.0%) compared to those receiving dialysis (21.5%).
There was a higher proportion of underweight children
in the dialysis group (8.0%) compared to those with
renal transplants (1.1%).
Of those aged 16 to,18 years, 44.4% were overweight
or obese compared to 23.7% of those aged 0 to ,5 years,
but there was no signiﬁcant difference by age in the trans-
plant patient group. There were no statistically signiﬁcant
differences between proportions of those underweight,
normal, overweight or obese in terms of sex, ethnicity
or donor source (deceased or living).
Hypertension
Figures 10.11 and 10.12 show paediatric patients
receiving RRT were hypertensive compared to the healthy
population, and those receiving dialysis had a signiﬁcantly
higher median SBP than those with renal transplants.
There was wide inter-centre variability in median SBP
z-score, with many centres having wide conﬁdence inter-
vals that included zero. The median SBP z-score was
maintained at or below the 90th percentile by all but
one centre for those with transplants whereas four centres
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Fig. 10.8. Median BMI z-scores for
transplant patients ,18 years old in 2014,
centre speciﬁc and national averages
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were above the 90th percentile for median SBP z-score for
those receiving dialysis. The overall median z-score was
0.4 in the transplanted group and 0.8 in the dialysis
group, p , 0.0001. Of those aged,18, 80.2% of children
with a functioning kidney transplant, 57.3% of those
receiving HD, and 70.3% of those receiving PD had a
SBP ,90th percentile in 2014. No comments can be
made at centre level or for dialysis patients due to small
patient numbers. Table 10.6 shows that there were
signiﬁcant differences in the percentage below the 90th
percentile for SBP between RRT modalities, gender, and
ethnicity. There was no statistically signiﬁcant difference
in SBP between age groups, HD and PD or between living
and deceased donor transplants.
Cardiovascular risk factor prevalence
Table 10.7 shows that the percentage of patients with
no CVRFs was 22.7%, one CVRF was 39.3%, two
CVRFs was 27.8% and the percentage of those with all
evaluated CVRFs was 10.3%. This analysis is restricted
to the 428 of 917 (46.7%) patients with complete data
for all three items. Thus of the included prevalent
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Fig. 10.11. Median systolic blood pressure
z-scores for transplant patients ,18 years
old in 2014, centre speciﬁc and national
averages
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Table 10.6. Percentage of patients ,18 years old achieving the
standard for systolic blood pressure in 2014
N
% below
90th percentile p value
Total 802 76.9
Age group (years) 0.07
0–,5 91 71.4
5–,12 310 73.6
12–,16 257 81.3
16–,18 144 79.9
Gender 0.0002
Male 501 81.2
Female 301 69.8
Ethnicity 0.007
Black 32 78.1
Other 54 75.9
South Asian 137 65.7
White 571 79.7
RRT modality ,0.0001
Dialysis 156 63.5
Transplant 646 80.2
Paediatric biochemistry Nephron 2016;132(suppl1):237–252 245
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f B
ris
to
l  
   
   
   
   
   
   
   
   
   
   
  
13
7.
22
2.
12
0.
22
6 
- 6
/8
/2
01
6 
1:
30
:1
8 
PM
paediatric RRT population three quarters had one or
more risk factors for cardiovascular disease, with 1 in
10 having all three risk factors evaluated. Of those
included in this analysis, 163 (38.1%) had hypertension,
189 (44.2%) were overweight/obese and 186 (43.5%)
had hypercholesterolaemia. There were no statistically
signiﬁcant differences in number of CVRFs according
to age, gender, ethnicity or modality.
Laboratory and clinical indices – quarterly data
Tables 10.8 and 10.10 display the median values and
interquartile ranges (IQR) for quarterly laboratory
parameters for paediatric transplant and dialysis patients
in 2014 by centre, with table 10.9 showing age speciﬁc
creatinine results. The total number of data points for
each parameter varied depending on completeness,
ranging from 2,059 data points for creatinine in trans-
plant patients to 430 data points for ferritin in dialysis
patients.
For transplant patients, these results demonstrate
excellent average graft function in the paediatric popu-
lation, with associated good anaemia control and normal
bone metabolism markers. The overall median ferritin in
transplant patients was 61 (IQR 32–139) mg/L based on
40% completeness. Similarly the overall median PTH in
transplant patients was 5.9 (IQR 3.9–8.9) pmol/L based
on 46% completeness, again likely to be unused in the
absence of transplant related chronic kidney disease.
For dialysis patients, the average haemoglobin and
ferritin were in target. For bone biochemistry, although
average calcium and phosphate were in range, there
was evidence of hyperparathyroidism with average PTH
Table 10.7. Frequency of number of cardiovascular risk factors in prevalent RRT patients ,18 years old in 2014
Number of CV risk factors Hypertensive OW/Obese Hypercholesterolaemic N % Total %
0 No No No 97 22.7 22.7
1 Yes No No 48 11.2
No Yes No 60 14.0 39.3
No No Yes 60 14.0
2 Yes Yes No 37 8.6
Yes No Yes 34 7.9 27.8
No Yes Yes 48 11.2
3 Yes Yes Yes 44 10.3 10.3
N 163 189 186
Total % 38.1 44.2 43.5
CV – cardiovascular; OW – overweight
Table 10.8. Median quarterly laboratory data by centre in prevalent transplant patients ,18 years old in 2014
Transplant patients
Centre
Creatinine
mmol/L
Haemoglobin
g/L
Calcium
mmol/L
Phosphate
mmol/L
Bicarbonate
mmol/L
Bham_P 71 120 2.45 1.32 25
Blfst_P 82 125 2.36 1.22 22
Brstl_P 71 125 2.45 1.28 25
Cardf_P 66 125 2.52 1.21 23
Glasg_P 81 118 2.44 1.27 21
L Eve_P 81 118 2.46 1.20 23
L GOSH_P 80 122 2.37 1.34 23
Leeds_P 91 116 2.38 1.32 25
Newc_P 83 127 2.41 1.23 23
Nottm_P 71 124 2.44 1.27 25
Overall median 79 121 2.41 1.29 24
Interquartile range (59–105) (111–131) (2.35–2.48) (1.13–1.43) (22–26)
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over target at more than twice the upper limit of normal,
with variation between centres. Control of acidosis was
also within the desired range.
Laboratory and clinical indices – annual data
Haemoglobin and ferritin
The percentage of patients aged ,18 on dialysis
achieving the haemoglobin standard in 2014 was 61.8%
for those on HD and 76.5% for those on PD, compared
to 92.5% for those with a renal transplant. There was
no pattern by age, and no comments could be made at
centre level or for dialysis patients due to small patient
numbers. During 2012–2014, 74.6% of dialysis patients
and 92.2% of transplant patients achieved the standard
for haemoglobin, which has remained consistent since
the 2003–2005 period. The proportion of patients with
a ferritin in range during 2012–2014 was 35.5% for
dialysis patients and 14.5% for transplant patients. It is
not possible to draw conclusions on ferritin data trends,
as the completeness for transplant patients was only
40.6% in the 2003–2005 period, but had improved to
77.5% in the 2012–2014 period. A similar improvement
Table 10.9. Median quarterly creatinine by age group and centre in prevalent transplant patients ,18 years old in 2014
Age group
0–,5 5–,12 12–,16 16–,18
Centre N
Creatinine
umol/L N
Creatinine
umol/L N
Creatinine
umol/L N
Creatinine
umol/L
Bham_P 14 41 92 63 95 83 26 94
Blfst_P 6 55 52 77 8 64 27 109
Brstl_P 7 45 90 60 27 83 33 102
Cardf_P 0 35 64 16 66 9 85
Glasg_P 4 51 39 59 57 94 13 119
L Eve_P 22 41 110 74 95 99 61 96
L GOSH_P 56 37 228 65 178 97 112 120
Leeds_P 10 42 76 80 96 97 51 99
Newc_P 4 34 13 41 40 83 40 100
Nottm_P 11 32 98 67 77 74 31 99
Total N and overall UK median 134 40 833 66 689 89 403 104
Interquartile range (33–49) (52–85) (71–114) (85–131)
Blank cell denotes missing data
Table 10.10. Median quarterly laboratory data by centre in prevalent dialysis patients ,18 years old in 2014
Dialysis patients
Centre
Haemoglobin
g/L
Ferritin
mg/L
Calcium
mmol/L
Phosphate
mmol/L
PTH
pmol/L
Bicarbonate
mmol/L
Bham_P 112 245 2.57 1.65 14.5 26
Blfst_P 117 1,117 2.46 1.03 21.8 27
Brstl_P 111 453 2.60 1.36 5.1 24
Cardf_P 114 316 2.61 1.36 44.2 22
Glasg_P 106 146 2.46 1.18 17.6 20
L Eve_P 108 334 2.48 1.50 31.1 24
L GOSH_P 117 203 2.47 1.39 9.0 25
Leeds_P 101 330 2.46 2.07 42.5 26
Newc_P 102 319 2.54 1.23 9.2 24
Nottm_P 103 229 2.50 1.21 21.8 30
Overall median 109 280 2.50 1.48 17.3 26
Interquartile range (98–121) (137–492) (2.41–2.61) (1.10–1.88) (6.9–46.0) (23–29)
PTH – parathyroid hormone
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was also seen for dialysis ferritin data, increasing from
72.9% to 94.8% over the same time periods.
At ﬁrst inspection, table 10.11 appears to show
increasing use of erythropoietin stimulating agents
(ESAs) over time in transplant patients and a decrease
in use of ESAs in dialysis patients over time. However
the amount of missing data increased from 2.5% in the
2003–2005 period to 22.5% in the most recent period
for dialysis patients, and by a similar margin for the
transplant patients.
Overall, ﬁgure 10.13 shows high usage of ESAs in
dialysis patients without a clear difference by haemo-
globin standard, noting erratic results from 2010 when
there was a reduction in data completeness. Usage of
ESAs in transplant patients remained low and reasonably
stable with a more discernible separation by haemoglobin
standard. Figure 10.14 is similar to ﬁgure 10.13 but
demonstrates wider variation for usage of intravenous
(IV) iron for dialysis patients by haemoglobin standard,
in keeping with low completeness for past years, and
low usage of IV iron in transplant patients.
Calcium
The percentage of patients aged,18 on HD (n = 102)
achieving the calcium standard in 2014 was 82.4%, with
5.9% of patients being hypocalcaemic, and 11.8% being
hypercalcaemic. The percentage of patients aged ,18
on PD (n = 86) achieving the calcium standard in 2014
was 72.1%, with no patients being hypocalcaemic, and
27.9% being hypercalcaemic. Small cohort numbers
prevent commentary at centre level or by age group.
Phosphate
The percentage of patients aged,18 on HD (n = 102)
achieving the phosphate standard in 2014 was 51.0%,
with 12.8% of patients being hypophosphataemic, and
36.3% being hyperphosphataemic. The percentage of
patients aged ,18 on PD (n = 86) achieving the
phosphate standard in 2014 was 53.5%, with 11.6% of
patients being hypophosphataemic, and 34.9% being
hyperphosphataemic.
Small cohort numbers prevent commentary at centre
level or by age group.
Parathyroid hormone
The percentage of patients aged ,18 with a renal
transplant (n = 605) achieving the PTH standard in
2014 was 83.5%, with 16.5% having hyperparathyroid-
ism. The percentage of patients aged ,18 on HD (n =
98) achieving the PTH standard in 2014 was 38.8%,
with 61.2% having hyperparathyroidism. The percentage
of patients aged ,18 on PD (n = 86) achieving the PTH
standard in 2014 was 32.6%, with 67.4% having
hyperparathyroidism. Small cohort numbers and low
Table 10.11. Proportion of paediatric RRT patients on ESA, by
haemoglobin attainment, across time
Time period
Hb below standard
% on ESA
Hb above standard
% on ESA
Transplant patients
2003–2005 20.2 3.8
2006–2008 22.9 4.6
2009–2011 22.2 6.9
2012–2014 26.0 4.3
Dialysis patients
2003–2005 96.6 92.3
2006–2008 94.9 95.7
2009–2011 88.1 80.7
2012–2014 85.5 90.2
Hb – haemoglobin; ESA – erythropoietin stimulating agent
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Fig. 10.13. The use of ESA by
haemoglobin standard and treatment
modality between 2003 and 2014 in
prevalent RRT patients ,18 years old
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completeness from some centres for transplant patients
prevent commentary at centre level or by age group.
Bicarbonate
The percentage of patients aged ,18 with a renal
transplant (n = 694) achieving the bicarbonate standard
in 2014 was 85.7%, with 10.4% being below the standard
and 3.9% being above the standard. The percentage of
patients aged ,18 on HD (n = 100) achieving the bicar-
bonate standard in 2014 was 75.0%, with 18.0% being
below the standard and 7.0% being above the standard.
The percentage of patients aged ,18 on PD (n = 86)
achieving the bicarbonate standard in 2014 was 68.6%,
with 5.8% being below the standard and 25.6% being
above the standard.
Small cohort numbers prevent commentary at centre
level or by age group.
Discussion
This chapter provides information describing clinical
and laboratory parameters of paediatric RRT patients in
the UK. This enables comparison against national stan-
dards and guidelines, assessment of quality of care and
benchmarking the performance of UK tertiary paediatric
nephrology centres. Data from 2014 and trends over the
last 12 years have been analysed. The results and con-
clusions are a valuable resource for the paediatric renal
community and this data accounts for nearly 20% of
European Paediatric Renal Registry data.
Major additions this year are (i) a section including quar-
terly data from 10 of 13 centres; and (ii) data on all patients,
including 16–18 year olds reported to the paediatric UKRR.
The efforts of the past few years have continued to improve
data quality to enable conclusions to be drawnwith greater
conﬁdence against a background of small patient numbers
from a relatively rare condition. An example of this is
seeking to receive quarterly rather than annual data to
ensure better representation from centres.
Quarterly data
Ten centres provided quarterly biochemistry data for
analysis. This has enabled the reporting of actual average
values for the parameters collected which is a major
change providing reassuring evidence of excellent graft
function for those with a transplant, and good control
of anaemia and acidosis in those on dialysis, perhaps
with some room for improvement for metabolic bone
disease management. The data presented has good
coverage of the UK with only one larger centre and two
smaller centres being omitted to date (Southampton did
provide quarterly data for height, weight and BP but
not biochemistry).
This progress moves the paediatric and adult renal
registry databases a big step closer to uniﬁcation which
would allow more comprehensive reporting, especially
of adolescents and young adults who may be managed
in paediatric or adult services.
The ongoing challenge is to continue to work with the
three remaining centres to achieve quarterly biochemistry
returns, and to improve extracts to allow new data to be
loaded into a single UKRR database.
Highlights from the 2014 data
For core items there was very good completeness.
Anaemia and growth hormone therapy data continues
to be patchy but more complete for dialysis patients.
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Fig. 10.14. The use of intravenous iron by
haemoglobin standard and treatment
modality between 2003 and 2014 in
prevalent RRT patients ,18 years old
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Growth
As previously reported, dialysis patients had lower
median height z-scores than transplanted patients, but
also only constitute approximately a ﬁfth of the popu-
lation. Median height z-scores were very comparable
between centres for both transplant and dialysis patients,
especially when completeness and conﬁdence intervals
are taken into account. The inclusion of 16–18 year
olds has not altered the median height z-scores suggesting
that the older patients are faring no worse in growth.
Over the last 15 years, the overall median height z-
score at RRT start is −1.4, demonstrating the impact of
a chronic disease in childhood and opportunities to
improve growth at earlier stages of chronic renal failure.
It is interesting to note that the median height z-score for
most transplant patients at ﬁve years was nearly the same
as that at start, so despite the need for RRT, patients
maintain their height, with the youngest transplant
patients improving their height z-score from a lower
value at RRT start.
The information on use of growth hormone remained
difﬁcult to interpret due to a high proportion of missing
data, and also there are many interventions to improve
growth (other than growth hormone therapy) which
the UKRR does not collect. Further, in situations where
use of growth hormone is not recommended (such as
in newly transplanted patients and in those demonstrat-
ing catch up growth) adjustment is not made in the
analyses.
While the median weight z-score for transplant
patients is quite close to that of the healthy population,
the data for dialysis patients show that they were more
underweight. As dialysis patients and transplant patients
were both shorter on average than their healthy peers,
this meant that transplant patients had a higher BMI
than their healthy peers with dialysis patients having a
relatively normal BMI. It would be interesting to relate
BMI to the use or not of steroids post transplantation.
Adding height and weight to the quarterly data (which
some centres are already providing) would allow calcu-
lation of growth rates.
Cardiovascular risk factor evaluation
The analysis of SBP across different centres in 2014
continued to show some differences between centres
although overall there has been some improvement in
SBP levels. An investigation to understand and identify
speciﬁc factors in transplant patients that have helped
some centres achieve improved BP control is
recommended.
In terms of the SBP standard, statistically fewer girls,
South Asians and dialysis patients achieved the target.
Further analysis also suggests primary renal diagnosis is
important with metabolic and tubulo-interstitial primary
renal diagnoses being associated with higher SBP. Further
analysis regarding this is planned for the next Annual
Report.
The prevalence of CVRFs was unchanged with 2014
data and the inclusion of 16–18 year olds, and although
only data on half the patients is included it is consistent
with previous evidence, including pre-dialysis CKD
cohorts [8–9]. Current data highlights concern regarding
this cohort. Last year the analysis showed hypertension to
be the most prevalent CVRF at 48% [10]. The data
including the older patients now shows being both over-
weight and having hypercholesterolaemia were the most
common at 44%, secondary to higher BMIs in the 16–
18 year olds. This suggests that weight should be a speciﬁc
target for intervention in the older patients.
Laboratory and clinical indices
Annual data regarding attainment of standards for
laboratory measures was similar to previous years for
haemoglobin, ferritin, calcium, phosphate, PTH and
bicarbonate. The proportion of dialysis patients achieving
the standards was rather low; however over-interpret-
ation of single measurements of variable completeness
from a small proportion of the cohort should be avoided.
The aim is to be able to report quarterly data for all
laboratory indices for all centres which will indicate
whether the standard achievements based on annual
data are indeed accurate.
Future work
The goals of the paediatric UKRR remain the reporting
of quarterly data for all paediatric renal centres, improv-
ing data extracts and then combining the adult and pae-
diatric UKRR databases.
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